Early Increased Ficolin-2 Concentrations are Associated with Severity of Liver Inflammation and Efficacy of anti-Viral Therapy in Chronic Hepatitis C Patients

Scandinavian Journal of Immunology

Volumn 77, Issue 2, 2013, Pages 144-150

  Hu, Y L ^a,b   Luo, F L ^a   Fu, J L ^c   Chen, T L ^a   Wu, S M ^d   Zhou, Y D ^e   Zhang, X L U ^a  

^a WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c BEIJING 302 HOSPITAL   (China)

^d Wuhan Medical Treatment Center   (China)

^e JIANGHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; FICOLIN; FICOLIN 2; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; LECTINS; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84872844989     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12014     Document Type: Article

References (37)

1. EI-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1273.
2. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003;362:2095-100.
3. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
4. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
5. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436:967-72.
6. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55:1350-9.
7. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010;327:291-5.
8. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune response. Cell Res 2010;20:34-50.
9. Song WC, Sarrias MR, Lambris JD. Complement and innate immunity. Immunopharmacol 2000;49:187-98.
10. Avirutnan P, Mehlhop E, Diamond MS. Complement and its role in protection and pathogenesis of Flavivirus infections. Vaccines 2008;26:1100-7.
11. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-66.
12. Holmskov U, Thiel S, Jensenius JC. Collections and ficolins: lectins of the innate immune defence. Annu Rev Immunol 2003;21:547-78.
13. Buck CB, Day PM, Thompson CD et al. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci USA 2006;103:1516-21.
14. Leikina E, Delanoe-Ayari H, Melikov K et al. Carbohydrate-binding molecules inhibit viral fusion and entry by cross-linking membrane glycoproteins. Nat Immunol 2005;6:995-1001.
15. Matsushita M, Endo Y, Taira S et al. A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin. J Biol Chem 1996;271:2448-54.
16. Endo Y, Sato Y, Matsushita M et al. Cloning and characterization of the human lectin P35 gene and its related gene. Genomics 1996;36:515-21.
17. Sugimoto R, Yae Y, Akaiwa M et al. Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J Biol Chem 1998;273:20721-7.
18. Harumiya S, Takeda K, Sugiura T et al. Characterization of Ficolins as Novel Elastin-Binding Proteins and Molecular Cloning of Human Ficolin-1. J Biochem 1996;120:745-51.
19. Zhang XL, Ali MA. Ficolins: structure, function and associated diseases. Adv Exp Med Biol 2008;632:105-15.
20. Runza VL, Schwaeble W, Männel DN. Ficolins: novel pattern recognition molecules of the innate immune response. Immunobiology 2008;213:297-306.
21. Krarup A, Mitchell DA, Sim RB. Recognition of acetylated oligosaccharides by human L-ficolin. Immunol Lett 2008;118:152-6.
22. Nahid AM, Sugii S. Binding of porcine ficolin-alpha to lipopolysaccharides from Gram-negative bacteria and lipoteichoic acids from Gram-positive bacteria. Dev Comp Immunol 2006;30:335-43.
23. Krarup A, Sørensen UB, Matsushita M, Jensenius JC, Thiel S. Effect of capsulation of opportunistic pathogenic bacteria on binding of the pattern recognition molecules mannan-binding lectin, L-ficolin, and H-ficolin. Infect Immun 2005;73:1052-60.
24. Esmat S, Omran D, Sleem GA, Rashed L. Serum mannan-binding lectin in egyptian patients with chronic hepatitis C: its relation to disease progression and response to treatment. Hepat Mon 2012;12:259-64.
25. Tong HV, Toan NL, Song LH et al. Ficolin-2 levels and FCN2 haplotypes influence hepatitis B infection outcome in vietnamese patients. PLoS ONE 2011;6:e28113.
26. Liu J, Ali AM, Shi Y et al. Specifically Binding of L-ficolin to N-glycans of HCV Envelope Glycoproteins E1 and E2 Leads to Complement Activation. Cell Mol Immunol 2009;6:235-43.
27. Seo YS, Jung ES, Kim JH et al. Significance of Anti-HCV Signal-to-Cutoff Ratio in Predicting Hepatitis C Viremia. Korean J Intern Med 2009;24:302-8.
28. Pan Q, Chen HD, Wang F et al. L-ficolin binds to glycoproteins HA and NA and inhibits influenza A virus infection both in vitro and in vivo. J Innate Immun 2012;4:312-24.
29. Candotti D, Temple J, Owusu-Ofori S, Allain JP. Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. J Virol Methods 2004;118:39-47.
30. Simmonds P, Bukh J, Combet C et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-73.
31. Lu L, Nakano T, He Y, Fu Y, Hagedorn CH, Robertson BH. Hepatitis V virus genotype distribution in China: predominance of closely relative 1b isolates and existence of new genotype 6 variants. J Med Virol 2005;75:538-49.
32. Hummelshøj T, Munthe-Fog L, Madsen HO, Fujita T, Matsushita M, Garred P. Polymorphisms in the FCN2 gene determine serum variation and function of Ficolin-2. Hum Mol Genet 2005;14:1651-8.
33. Hummelshøj T, Munthe-Fog L, Madsen HO, Garred P. Functional SNPs in the human ficolin (FCN) genes reveal distinct geographical patterns. Mol Immunol 2008;45:2508-20.
34. Hadziyannis SJ, Sette HJ, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
35. Hui C-K, Monto A, Belaye T, Lau E, Wright TL. Outcomes of interferon α and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases. Gut 2003;52:1644-8.
36. Terajima M, Cruz J, Co MD et al. Complement dependent lysis of influenza A virus-infected cells by broadly cross-reactive human monoclonal antibodies. J Virol 2011;85:13463-7.
37. Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007;40:560-6.